Athersys, Inc (ATHX)
Company Address: 3201 Carnegie Ave Cleveland, Ohio 44115-2634 T: 216-431-9900 F: 216-361-9495 info@athersys.com CIK: 0001368148
Athersys, Inc. fundamental goals are to create safer and more effective new therapies that can address significant unmet medical needs and to generate substantial value for our shareholders in the process. We are committed to developing a portfolio of product development opportunities that we believe have the potential to be safer, more effective products than the current standard of care or other products in development that we are aware of, and that may have other advantages, such as superior scalability or ease of administration. By applying our distinctive technologies and capabilities, and by utilizing certain approaches to minimize development risk and costs, we believe that we achieve our goals while also being cost effective.
Management: http://www.athersys.com/management.cfm?s=about Clinical Programs: http://www.athersys.com/clinicalPrograms.cfm Recent News: http://finance.yahoo.com/q/h?s=ODP+Headlines SEC Filings: http://www.sec.gov/edgar/searchedgar/companysearch.html Share Structure: See SEC filings Transfer Agent: Computershare 250 Royall Street Canton, MA 02021 T: 781-575-2598 F: 781-575-4647 Investor Relations: info@athersys.com 
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose. Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn’t a sign of endorsement. Please keep your posts on topic because your message(s) will probably be deleted when: * Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:
http://investorshub.advfn.com/boards/complex_terms.asp